Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors
Open Access
- 17 April 2020
- journal article
- review article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (8), 2475-2486
- https://doi.org/10.1210/clinem/dgaa200
Abstract
Intro Sodium glucose cotransporter 2 inhibitors (SGLT2i) have emerged as an important class of blood glucose lowering medications due to cardiovascular, metabolic and renal benefits. However, there is a small but significant risk of diabetic ketoacidosis (DKA) associated with their use. Methods A literature search was conducted in Ovid MEDLINE and Embase to July 2019 using variants on the key search terms sodium-glucose cotransporter 2, diabetic ketoacidosis and type 2 diabetes. A broad spectrum of evidence was incorporated to facilitate a comprehensive narrative review. Further sources were identified through hand searching of reference lists. Discussion Although cardiovascular outcome trials demonstrated mixed evidence of SGLT2i associated DKA, increasing evidence from case reports and cohort studies has identified an increased risk. SGLT2i use is associated with a ketotic state caused by an increased glucagon-insulin ratio and stimulated by factors including stress-induced hormonal changes, insufficient insulin, decreased glucose, increased ketone resorption and hypovolemia. Atypical presentations of DKA with lower than expected blood glucose levels are possible with SGLT2i use, so clinical and biochemical monitoring is vital for early identification and management. DKA risk is particularly increased with precipitating factors, therefore optimization of risk factors is vital. Recommendations for peri-operative and sick day management of patients taking SGLT2i have been suggested based on available evidence. Conclusion SGLT2i are an excellent class of drug in the physician’s toolkit for managing type 2 diabetes. However, both clinicians and patients must be aware of the potential for DKA and the need for increased monitoring, both clinically and biochemically, when potential precipitating factors are present. In acutely unwell patients, these medications should be withheld to reduce the risk of DKA.Keywords
Funding Information
- Bayer
- Sanofi
- Novo Nordisk
- Gilead
This publication has 71 references indexed in Scilit:
- American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic KetoacidosisEndocrine Practice, 2016
- The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and managementMetabolism, 2015
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factorsJournal of Diabetes Investigation, 2015
- Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitusAnnals of the New York Academy of Sciences, 2015
- SGLT2 Inhibitors May Predispose to KetoacidosisJournal of Clinical Endocrinology & Metabolism, 2015
- Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequencesDiabetes and Vascular Disease Research, 2015
- Hypoglycemia and Risk of Death in Critically Ill PatientsThe New England Journal of Medicine, 2012
- Etiology and effect on outcomes of hyperglycemia in hospitalized patientsAmerican Journal of Health-System Pharmacy, 2007
- Ketoacidosis during a Low-Carbohydrate DietThe New England Journal of Medicine, 2006